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Abstract 
There is a growing interest in the pivotal role of exosomes in cancer and in their use as biomarkers. 
However, despite the importance of the microenvironment for cancer initiation and progression, 
monolayer cultures of tumor cells still represent the main in vitro source of exosomes. As a result, their 
environmental regulation remains largely unknown. Here, we report a three-dimensional tumor model 
for studying exosomes, using Ewing’s sarcoma type 1 as a clinically relevant example. The bioengineered 
model was designed based on the hypothesis that the 3-dimensionality, composition and stiffness of the 
tumor matrix are the critical determinants of the size and cargo of exosomes released by the cancer 
cells. We analyzed the effects of the tumor microenvironment on exosomes, and the effects of 
exosomes on the non-cancer cells from the bone niche. Exosomes from the tissue-engineered tumor 
had similar size distribution as those in the patients’ plasma, and were markedly smaller than those in 
monolayer cultures. Bioengineered tumors and the patients’ plasma contained high levels of the 
Polycomb histone methyltransferase EZH2 mRNA relatively to their monolayer counterparts. Notably, 
EZH2 mRNA, a potential tumor biomarker detectable in blood plasma, could be transferred to the 
surrounding mesenchymal stem cells. This study provides the first evidence that an in vitro culture 
environment can recapitulate some properties of tumor exosomes. 
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Introduction 
Exosomes are small membrane vesicles of 
endocytic origin that are released into the 
extracellular environment and circulate in the blood 
stream [1, 2]. They contain cell-specific cargo 
molecules (i.e. proteins, mRNA, miRNA, DNA), 
membrane proteins, and lipids. Consequently, 
exosomes are finding application as diagnostic 
biomarkers in a number of cancers [3-6]. Also, 
tumor-derived exosomes were shown to transfer a 
variety of bioactive molecules to other cells, inducing 
modifications of their environment and facilitating 
tumor growth and invasion [7]. There is an increasing 
interest in understanding how exosomes modulate 
their environment, after the discovery of their role in 
the pre-metastatic niche formation in lung [8] and 
liver [9]. 
Our knowledge about the putative roles of the 
microenvironment on tumor exosomes is limited, due 
to a lack of experimental models that efficiently mimic 
the human in vivo situation. Animal models used to 
study the effects of exosomes on cancer development 
often fail in representing the context of human disease 
[10]. In vitro, cancer cells are typically cultured under 








environment [11]. The absence of physiological 
cell-cell and cell-matrix-interactions and the currently 
used non-physiological substrates cause disparity 
from the in vivo situation and lead to changes in cell 
morphology, proliferation and cellular processes, 
such as endo- and exocytosis [11, 12]. Despite the 
growing notion of the importance of cell 
microenvironment for cancer signaling [13], 
supernatants from monolayer cultures still represent 
the main source of tumor-derived exosomes, such that 
their microenvironmental regulation remains largely 
unknown. Bioengineering methods are just about 
starting to bridge the gap between studies in cell 
monolayers and experimental animals, providing the 
models of human tumors that enable studies of how 
the microenvironment modulates cancer biology [14, 
15]. 
Here we describe a controllable 3D 
tissue-engineered model for studying tumor 
exosomes, designed to mimic the native tumor 
microenvironment. As a clinically relevant example, 
we selected Ewing’s sarcoma (ES), a solid tumor with 
aggressive biologic behavior [16], that affects children 
and young adults, and is associated with frequent 
metastases and poor prognosis [17]. ES is 
characterized by chromosomal rearrangements of the 
EWSR1 (22q12) gene with one of the members of the 
ETS family of transcription factors: the FLI1 gene 
(11q24) in 85% of cases [18]. Expression of 
EWSR1-FLI1 fusion protein has been the main 
approach to study the development of ES [19-22]. 
Recent studies also demonstrated the presence of 
EWSR1-FLI1 mRNA in ES–derived exosomes [23, 24].  
Human mesenchymal stem cells (hMSC) were 
the only cell type found to provide an appropriate 
cellular context for EWSR1-FLI1 expression, 
supporting the notion that Ewing’s sarcoma is 
derived from hMSCs [20, 21]. Surprisingly, hMSCs 
were unable to form tumors in immunocompromised 
mice [21]. Taken together, the published studies show 
that EWSR1-FLI1 is necessary to activate the 
oncogenic program, but not sufficient for oncogenic 
transformation of hMSCs [17]. Therefore, recent 
research has focused on downstream transcriptional 
targets [25-27] such as EZH2. EWSR1-FLI1 was shown 
to bind to the EZH2 promoter and to induce EZH2 
expression in Ewing’s sarcoma in vivo and hMSCs in 
vitro [28]. The EZH2 methyltransferase is a major 
component of the Polycomb repressive complex 2 
(PRC2) that is related to transcriptional repression of 
tumor suppressors such as p14ARF and p16INK4a [29]. 
EZH2 is involved in the maintenance of cell 
pluripotency [30-32] and oncogenic transformation of 
Ewing’s sarcoma cells [28]. Additionally, expression 
of EZH2 correlates with poor prognosis in several 
tumor types [33-35] including ES [28]. Thus far, the 
presence of EZH2 in ES-derived exosomes has not 
been documented.  
Our goal was to capture both the effects of the 
microenvironment on tumor-derived exosomes, and 
the effects of exosomes on cell populations in the bone 
niche. To this end, we cultured ES cells in 
3-dimensional biomaterial scaffolds designed to 
mimic the biological and mechanical properties of ES. 
We analyzed and compared the size distributions and 
EZH2 mRNA cargo in exosomes from the plasma of 
patients and culture medium from 2D monolayers (in 
culture dishes with different matrix coatings), 3D cell 
aggregates (in polypropylene), and 3D 
tissue-engineered tumors (in scaffolds resembling 
native tumor matrix) (Fig.1A). We then investigated 
the transfer of EZH2 mRNA from tumor-secreted 
exosomes to the mesenchymal stem cells, osteoblasts 
and osteoclasts of the ES bone niche.  
Materials and Methods  
Collection of the tissue samples from patients. 
Fully de-identified Ewing’s sarcoma tumors were 
obtained from the Columbia University Tissue Bank, 
on an IRB-approved protocol. Frozen 
tissue samples from three different patients 
were cut into sets of contiguous sections for 
mechanical, histological, and immunohistochemical 
studies.  
Fully de-identified blood plasma samples from 
Ewing’s sarcoma patients for exosome isolation and 
characterization were collected in Dr. Moore’s 
laboratory on an IRB-approved protocol at Memorial 
Sloan-Kettering Cancer Centre (New York, USA). 
Scaffold preparation. Highly porous scaffolds 
were produced from Col1-HA solutions by 
freeze-drying. A 1% (wt/v) solution was prepared 
from low molecular weight (10-20 kDa) or high 
molecular weight (500 kDa) Sodium Hyaluronate 
(HA, Lifecore, US) in distilled water. Four parts of 
Collagen 1 solution (8-11 mg/ml in 0.02 N Acetic acid 
Corning, US) were mixed with one part of HA 
solution (4:1). After mixing, 200 μl of the solution was 
spread over a 8 mm x 5.5 mm mold, frozen at −40 °C 
for 4 hours, and sublimed at -40°C overnight under a 
vacuum of < 100 mTorr. 
Lyophilized collagen–HA scaffolds were 
cross-linked with a water-soluble carbodiimide using 
a previously described method [36]. Scaffolds were 
immersed in 95% ethanol solution containing 33 mM 
EDC (Sigma–Aldrich Co. Ltd., UK) and 6 mM NHS 
(Sigma–Aldrich Co. Ltd., UK) for 4 h at 25 °C. After 
crosslinking, the scaffolds were washed thoroughly in 
distilled water (5 min × 5 times), refrozen and 
re-lyophilized at the same freeze-drying cycle as 





Preparation of matrix-coated plates. Three 
different types of solutions were prepared for coating 
culture plates. For collagen-coated plates, a solution of 
collagen 1 (8-10 mg/mL, BDTM) was diluted in 
distilled water (4:1 dilution ratio). For HA coated 
plates, a suspension of HA (1% weight) was prepared 
from the low molecular weight sodium hyaluronate 
(10-20 kDa, Lifecore biomedical) in distilled water. For 
Col 1/HA coated plates, the above solutions of 
collagen 1 and HA were mixed in the 4:1 ratio of Col1: 
HA. 2mL of each of the three above solutions were 
added into each well of a 6-well plate, and left for 1h 
at room temperature in a sterile hood. The remaining 
unattached solutions were carefully aspirated. Each 
well was plated with 0.3 x106 SK-N-MC cells. 
Culture of cells in aggregates and in 3D 
scaffolds. Ewing’s sarcoma cell line SK-N-MC 
(HTB-10) was purchased from the American Type 
Culture Collection (ATCC) and cultured according to 
the manufacturer's specifications, in ATCC- 
formulated Eagle's Minimum Essential Medium 
(EMEM) supplemented with 10% (v/v) Hyclone FBS 
and 1% penicillin/streptomycin. 
To form tumor cell aggregates, 0.3 x106 
SK-N-MC cells were centrifuged in 15 mL Falcon 
tubes, 5 minutes at 1200 rpm, with 4 mL of medium 
and cultured for 7 days at 37°C in a humidified 
incubator at 5% CO2. 
To seed 3D Collagen 1-HA scaffolds, single-cell 
suspension of SK-N-MC cells was adjusted to the cell 
concentration of 1 x106 cells/mL in a 50 ml Falcon 
tube. A total of 15 scaffolds were added to 30 mL of 
cell suspension, and the Falcon were set onto a rotary 
platform for 3h at 37°C/5% CO2. Cell seeded scaffolds 
were then transferred to non-treated wells in 
12-multiwell plates (Nunc) and cultured in 2 mL of 
medium at 37°C / 5% CO2. Cell numbers and were 
determined by Quant-iT PicoGreen dsDNA Assay Kit 
(Life technologies) according to the manufacturer’s 
instructions. 
Mechanical testing. The mechanical properties 
of native Ewing’s sarcoma tumors collected from the 
patients at the Memorial Sloan-Kettering Cancer 
Centre (New York, USA) were measured using a 
previously established protocol [37]. Briefly, the 
Young’s modulus was determined under unconfined 
compression in phosphate-buffered saline (PBS) at 
room temperature. An initial tare load of 0.2 N was 
applied, and followed by a series of stress-relaxation 
steps, where specimens were compressed at a ramp 
velocity of 1% per second up to the 10% strain, and 
maintained at each position for 1,800 s. The Young’s 
modulus was calculated from the equilibrium force 
measured at the 10% strain. 
Scanning Electron Microscopy (SEM). The 
morphology of the bioengineered tumors was 
examined by SEM. Samples were washed twice in PBS 
and fixed in 4% paraformaldheyde in PBS (Santa 
Cruz, US) for 1 hour. Fixed specimens underwent a 
graded dehydration series of ethanol (70, 85, 95, 100% 
for 5 min each) and hexamethyldisilazane drying for 
15 min (HMDS, Sigma). Samples were dried over 
night in the fume hood, sputter-coated with gold and 
palladium, and imaged using SEM (Hitachi S-4700). 
Fluid Uptake by the Scaffolds. Dried samples 
were weighed (Wd) and immersed in distilled water 
at 37°C for different periods of time (2 hours, 3, 7 and 
10 days). At each time point, specimens were 
removed from distilled water and the ability of the 
scaffold structure to absorb water was measured 
using a previously described method [36]. At each 
time point, the samples were removed from water and 
weighed (Ww). The water uptake was calculated as: 
Fluid uptake (%) = (Ww–Wd)/Wd x 100. Each sample 
was measured in triplicate. 
Scaffold degradation. Dried samples were 
weighed (Wd) and immersed in distilled water at 
37°C in a humid atmosphere for timed intervals (2 
hours, 3, 7 and 10 days). At each time point, 
specimens were removed from distilled water, 
air-dried for 24 h and weighed (Wa). The weight loss 
was calculated as: Weight loss (%) = (Wd–Wa)/Wd x 
100. Each sample was measured in triplicate.  
Histology and immunohistochemistry (IHC). 
Frozen sections of the native Ewing’s sarcoma tumors 
and bioengineered tumors were fixed in pre-cooled 
acetone (-20 oC) for 10 min. Sections were washed 
with PBS and treated with 0.3% H2O2 solution in PBS 
at room temperature for 10 min to block endogenous 
peroxidase activity, and incubated with a blocking 
buffer from Vectastain Elite ABC Kit (Vector Labs), 
according to the manufacturer’s instructions. Then, 
sections were stained for CD99 (dilution 1:500; Signet 
antibodies, SIG-3620) and Collagen 1 (dilution 1:500; 
Abcam, ab34710). Slides were counterstained with 
Hematoxylin QS (Vector Labs).  
For the hyaluronan acid binding protein (HABP) 
staining, the sections were blocked using 1% BSA in 
HBSS at room temperature for 30 min, and incubated 
with a biotinylated HABP antibody (dilution 1:100; 
Millipore #385911). A Streptavidin Alexa fluor 488 
conjugate (dilution 1:500; Molecular Probes) was used 
as the secondary antibody.  
Live-Dead assay. At timed intervals (day 3 and 
day 7), Bioengineered tumor models were incubated 
in EMEM medium containing 2μM Calcein and 4μM 
of ethidium homodimer-1 for 30 min at 37°C, 5% CO2, 
as indicated by the manufacturer’s protocol 
(LIVE/DEAD® Viability/Cytotoxicity Kit, Molecular 




Probes). Samples were imaged with a fluorescence 
microscope (Olympus IX81 light microscope, Center 
Valley PA). 
Exosome isolation and size analysis. Cells 
cultured in monolayers, aggregates and 3D scaffolds 
were washed with PBS twice and cultured in EMEM 
supplemented with 10% (v/v) Exosome-depleted FBS 
(SBI) and 1% penicillin/streptomycin for 12h. The 
supernatants were collected and exosomes were 
isolated from cell culture media using the total 
exosome isolation kit (Invitrogen), according to the 
manufacturer's protocol. Exosomes from plasma 
samples were also isolated using the total exosome 
isolation kit (Invitrogen). The size distributions of 
exosomes were determined by Nanoparticle Tracking 
Analysis (NTA) using the Nanosight machine. 
Genomics Analysis. Overexpression of EZH2 in 
Ewing’s sarcoma tumors at mRNA levels were 
compared using the R2 Genomics Analysis and 
Visualization Platform (http://r2.amc.nl.) The R2 
platform is an online genomics analysis tool that can 
analyze a large collection of public data. We selected 
EZH2 as gene of interest to generate a MegaSampler 
using the following dataset:  
Tumor Ewing Sarcoma-Francesconi (37 
samples). Source: GEO ID: gse34620 Dataset Date: 
2000-01-01. Pubmed link: 22327514. A genome-wide 
association study of at least 401 French ES patients 
compared to either 684 French or 3668 US 
self-described Caucasian controls consistently 
revealed candidate loci at chromosomes 1 and 10 
(p<10-6). 
Tumor Ewing Sarcoma-Delattre (117 samples). 
Source: GEO ID: gse12102 Dataset Date: 2008-06-15. 
Pubmed link: 22327514. Available tracks in R2: group 
(CAT) [ ews metastasis tumor (metastasis) | ews 
primary tumor (no evidence of disease) | ews 
primary tumor (relapse)] 
Healthy: Normal Various –Roth- (353 samples). 
Source: GEO ID: GSE3526 Dataset Date: 2006-03-30. 
Pubmed link: 16572319. Normal human tissue 
samples from ten post-mortem donors were 
processed to generate total RNA, which was 
subsequently analyzed for gene expression using 
Affymetrix U133 plus 2.0 arrays. Donor information: 
Donor 1 - 25 year old male; donor 2 - 38 year old male; 
donor 3 - 39 year old female; donor 4 - 30 year old 
male; donor 5 - 35 year old male; donor 6 - 52 year old 
male; donor 7 - 50 year old female; donor 8 - 48 year 
old female; donor 9 - 53 year old female; donor 10 - 23 
year old female. 
Quantitative real-time PCR (qRT-PCR). Total 
RNA from cells was obtained using Trizol (Life 
Technologies) and total RNA from exosomes was 
obtained using the Total Exosome RNA & Protein 
Isolation Kit (ThermoFisher scientific) following the 
manufacturer’s instructions. RNA preparations were 
treated with “Ready-to-go you-prime first-strand 
beads” (GE Healthcare) to generate cDNA. 
Quantitative real-time PCR was performed using 
DNA Master SYBR Green I mix (Applied Biosystems). 
mRNA expression levels were quantified applying 
the ΔCt method, ΔCt = (Ct of gene of interest - Ct of 
Actin). EZH2 primers were obtained from the 
PrimerBank database (http://pga.mgh.harvard.edu/ 
primerbank/). 
RNA quality. Total RNA quality and size 
distribution from cells and exosomes were 
determined by electropherograms from the 
Bioanalyzer 2100 using the RNA Pico Chip kit 
(Agilent Technologies). 
Western blot. Cells were lysed in RIPA buffer 
containing protease inhibitors (Sigma-Aldrich, P8340) 
and exosomes extracts were obtained using the Total 
Exosome RNA & Protein Isolation Kit (ThermoFisher 
scientific) following the manufacturer’s instructions. 
Cell preparations were centrifugated at 12,000 g for 10 
min and supernatants containing soluble proteins 
were collected for analysis. 20μg of cells and 
exosomes extracts were loaded on 4-12% gradient 
Bis-Tris gels (BioRad), transferred to a nitrocellulose 
membrane and incubated with antibodies against 
EZH2 (1:500; Millipore 07-689), Calnexin (1:500; Santa 
Cruz, sc-11397, CD81 (1:500; Santa Cruz, sc-7637) at 4 
degrees over night and GAPDH (1:5000; Invitrogen 
437000) at room temperature for one hour. For 
detection, membranes were incubated with a 
secondary antibody anti-rabbit or anti-mouse 
conjugated with Alexa Fluor 680 dye (1:5000; 
ThermoFisher Scientific) at room temperature for one 
hour and imaged on Licor Odyssey scanner.  
Exosome-mediated transfer of RNA. SKNMC 
cells were cultured on Col1-HA scaffolds for 7 days in 
ATCC-formulated Eagle's Minimum Essential 
Medium (EMEM) supplemented with 10% (v/v) 
Hyclone FBS and 1% penicillin/streptomycin. For 
exosome isolation, cells were cultured with 10% 
Exosome-depleted FBS (SBI) and 1% 
penicillin/streptomycin for 12h. Supernatants were 
harvested and exosomes were isolated. To measure 
protein concentration (by Bradford assay), the 
concentration of protein was adjusted to ~ 0.1 µg/µL 
in PBS, and the samples were diluted 1:50 (20µl in 1ml 
of PBS) for NTA analysis. The same volumes, 
dilutions and the same camera shutter were used to 
obtain similar concentrations of particles for 
measuring size distributions in cell monolayer and 
TE-Tumors.10µg of exosomes protein were labeled 
with SYTO RNA Select green fluorescent (Invitrogen) 
during 30 min at 37°C/5% CO2 at a final dye 




concentration of 10 μM. Exosome Spin Columns (MW 
3000) were used to remove unincorporated dye from 
exosome labeling. The same volume of PBS without 
exosomes was also treated with SYTO RNA and Exosome 
spin columns to serve as a control. Cells (5,000 cells/well) 
were seeded in a 8-wells chamber slide the day before 
the exosome-mediated transferring assay. 10 µg of 
labeled exosomes in PBS, or same volume of PBS 
control, were incubated with hMSC passage 3, human 
osteoblasts or human osteoclasts during 2h at 
37°C/5% CO2. Cells were fixed for 20 min with 4% 
PFA in PBS and mounting with Vectashield-DAPI.  
Results  
Bioengineered tumor model. Native Ewing’s 
sarcoma (ES) is a pediatric tumor rich in collagen 1 
(Col1) and hyaluronic acid (HA) proteins (Fig. S1A), 
and soft tissue matrix characterized by an equilibrium 
modulus of ~2 kPa (Fig. S1B). In order to mimic the 
composition and mechanical properties of the ES 
extracellular matrix, we used purified preparations of 
natural Col1 and HA (low molecular weight, LMW; 
high molecular weight, HMW) with a stiffness 
matching that of the native tumor (Fig. S1B). Two 
types of 3D porous scaffolds (Col1-HA LMW; 
Col1-HA HMW) were made by freeze-drying of 
Col1/HA solutions, and cross-linking with 1-ethyl-3- 
(3-dimethylaminopropyl)-carbodiimide hydrochlo-
ride, EDC, in the presence of N-hydroxysuccinimide, 
NHS (Fig. S1C).  
The swelling behavior, measured by the liquid 
uptake, was similar for the two porous scaffolds, and 
in agreement with the previous studies [36]. The rate 
of degradation was much slower for Col1-HA LMW 
than Col1-HA HMW scaffolds, presumably due to the 
higher density of chemical cross-links (Fig. S1D). 
These results demonstrated that the Col1-HA LMW 
scaffold was suitable for supporting the in vitro 
culture of tumor cells. In previous studies, LMW HA 
was shown to play a role in tumor progression in a 
number of cancers [38-42]. Therefore, we selected the 
Col1-HA LMW scaffold as an appropriate biomimetic 
environment for culturing ES cells.  
To bioengineer the most common ES tumor type, 
we cultured the SK-N-MC cell line (type 1 
rearrangement) in Col1-HA LMW scaffolds. 
Mechanical properties of the TE-tumor did not change 
over time (Fig. 1B), and the model was stable over one 
week of culture. The proliferation of ES cells cultured 
within the TE-tumor model was slower than when the 
same cells were cultured in monolayer (Fig. 1C), 
consistent with the known lower rates of cell 
proliferation in native tumors compared to cancer 
cells cultured in monolayers [43]. Live/Dead analysis 
demonstrated uniform distribution of cells 
throughout the scaffolds at day 3 and day 7, and 
showed that most of the cells were viable after 7 days 
of culture (Fig. S2). 
Notably, the levels of expression of CD99 in the 
TE tumor model were comparable to those measured 
in the samples of patients’ tumors (Fig. 1D). These 
data show that cell culture on Col1/HA scaffolds does 
not modify the levels of this important membrane 
protein that is highly expressed in most cases of 
Ewing’s sarcoma and maintains them at levels similar 
to those in tumors from patients. The cells cultured in 
the TE-tumor model formed small avascular 
aggregates that increased in size over time, mimicking 
the initiation of native tumor formation (Fig. 1 E, F).  
Evaluation of the purity of exosomes 
preparations. In order to check the purity of the 
exosome preparations, we performed two sets of 
analysis consisting in protein composition and total 
RNA profiles [44, 45]. Toward this end, first we 
analyzed the levels of the CD81 (exosomal marker) 
and calnexin (only detectable in cellular and apoptotic 
bodies extracts), in monolayer and the TE tumor 
model at day 3 and day 7 (Fig. S3A). We also 
determined GAPDH levels to address the possibility 
of using GAPDH as a loading control of the technique. 
We confirmed the absence of calnexin in the 
extracellular preparations. This suggests that there is 
not cellular or apoptotic bodies contamination in the 
exosomes preparations. CD81 was detectable in 
exosomes preparations from cells in monolayer but 
not from TE-tumors preparations. GAPDH levels 
were similar between samples that points GAPDH as 
a good loading control.  
Then, we further analyzed the quality of the 
exosomes isolation by analyzing RNA profiles from 
cells and exosomes preparations from cells in 
monolayer and TE-tumor at day 7, using the 
Bioanalyzer 2100 (Fig. S3B). As expected, 
electropherograms showed different RNA size 
distributions between samples. The RNA profile from 
cells revealed two dominant peaks, corresponding to 
the ribosomal RNA (rRNA) subunits 18S and 28S. 
Both peaks are also observed in RNA profiles from 
preparations of apoptotic bodies [46]. The RNA 
profile from extracellular vesicles lacked of both 
rRNA peaks and showed and enrichment in small 
RNAs, accordingly with the literature [46].  
Exosome size. Using the Nanoparticle Tracking 
Analysis (NTA), we determined the size distributions 
of exosomes released into the culture media from the 
bioengineered tumor and from cell monolayers, and 
compared these to the size distributions of exosomes 
secreted into the blood plasma of ES patients. The 
sizes of exosomes isolated from human plasma 
(average mean ± SD: 88.7 ± 22 nm; average mode ± 




SD: 70.0 ± 20 nm, n=7 patients, Fig. 2A) were 
consistent with the previously reported data [2], and 
significantly smaller than the exosomes from 
monolayer cultures of ES cells (average mean ± SD: 
149.2 ± 19 nm; average mode ± SD = 103.3 ± 23 nm, 
n=3, ∗∗p < 0.01; Fig. 2A). In addition, the numbers of 
particles per unit protein were not statistically 
different for cell monolayers and tissue engineered 
tumors (Fig. S4). Notably, the sizes of exosomes 
released from tumor models (average mean ± SD: 
113.4 ± 10 nm, average mode ± SD: 76.7, ± 10.3 n = 6; 
Fig. 2A) were indistinguishable from those in the 
patients’ plasma. These data suggest that the 
3-dimensionality or composition of the scaffold (or 
both of these factors) regulate the exosomes to reach 
their native size. To distinguish the relative 
contributions of the matrix 3-dimensionality and 
composition, we investigated the sizes of exosomes in 
multiple model systems. 
To evaluate the role of 3-dimensionality, we 
generated ES cell aggregates in a generic 
polypropylene context, in the range of sizes that we 
have observed for bioengineered tumors at day 7 (Fig. 
2B). Neither the average mean nor the mode size of 
exosomes isolated from these aggregates 
recapitulated the values found in the patients’ plasma 
(Fig. 2B). Mimicking the tumor size and morphology 
using 3D models without a biomimetic context was 
thus not sufficient to recapitulate the native exosome 
size.  
To evaluate the role of matrix composition, we 
cultured ES cells in monolayers formed on 
polystyrene dishes coated with different extracellular 
matrix proteins (HA LMW, Col1, Col1-HA LMW, Fig. 
2C). We could not observe any difference in the mean 
size or mode of exosomes secreted by the ES cells 
cultured on uncoated polystyrene dishes and on 
dishes coated with the proteins used for fabricating 
the scaffolds (Fig. 2D). These results indicate that 
mimicking the native matrix composition without 
providing the native stiffness and 3D context was also 
not sufficient for reproducing the native size of 
exosomes. Providing both the 3-dimensionality of cell 
culture and the composition of extracellular matrix 




Figure 1. Ewing’s sarcoma type 1 model in a 3-dimensional Collagen 1- Hyaluronic acid scaffold (A) Model systems used to isolate and analyze exosome size and 
cargo: plasma from patients and supernatants from cells cultured in vitro. (i) Hematoxylin and Eosin staining of Ewing’s sarcoma (ii) cartoons representing the different sources of 
exosomes isolation from supernatants (cells on dish, cells on coated dish, aggregates and cells in scaffold) (B) Equilibrium modulus of Col1-HA LMW initial scaffolds (n=3) and 
cell-seeded scaffolds (n=3) at indicated time points. (C) Cell proliferation evaluated by changes in numbers of cells over time for SK-N-MC cells cultured in monolayers and in 
scaffolds. Statistical significance was determined by the two-tailed Student’s t test at day 7; ***p < 0.001. (D) CD99 protein levels in SK-N-MC cells cultured in scaffold at day 3 
(TE-tumor d3) and day 7 (TE-tumor d7) compared to cell monolayers (ML) and Ewing’s sarcoma tumors (ES). (E) Hematoxylin and Eosin staining of bioengineered tumors 
(SK-N-MC cultured in Col1-HA scaffolds) at day 3 and day 7. (F) Formation of cell aggregates and cell-matrix integration in bioengineered tumors at day 7, by Hematoxylin and 
Eosin staining (left) and Scanning Electron Microscopy (SEM) (right). 





Figure 2. Recapitulation of exosomes’ size in the bioengineered tumors. (A) Exosome size analysis for SK-N-MC cells cultured in monolayers (n=3) and into Col1-HA 
scaffolds (n=6) at day 3 (ML d3 and SF d3, respectively), compared to the plasma from Ewing’s sarcoma patients (n=7), by Nanoparticle Tracking Analysis (NTA, Nanosight 
instruments). (B) Distribution of exosome sizes in plasma of Ewing’s sarcoma patients (n=7) and cell aggregates generated in polypropylene environment at day 7 (n=7), by 
Nanoparticle Tracking Analysis. Inset: Hematoxylin and Eosin staining of a representative SK-N-MC cell aggregate in polypropylene context, with a necrotic core, at day 7. (C) 
Bright field images of SK-N-MC cells cultured for 3 days in monolayers, on plates coated with Hyaluronic acid (+HA), Collagen 1 (+ Col-1), and Collagen 1-Hyaluronic acid 
(+Col1/HA). Representative images are shown (n=3 per condition). (D) Exosome size distribution for SK-N-MC cells cultured in monolayers HA-coated (n=3), Col-1-coated 
(n=3) and Col1-HA-coated (n=3) compared to SK-M-C cells cultured on uncoated culture plates (control; n=3) (E) Analysis of the effect of blebbistatin on cell aggregates in 
Col1-HA scaffolds (Hematoxylin and Eosin staining), and (F) on exosome’s size, by NTA; (n=3 per condition). 
 
To probe a possible mechanism underlying the 
observed effects of the tumor environment on 
exosome size, we modified the tension forces within 
the cells. To this end, we maintained the 
3-dimensionality, composition and stiffness of the 
microenvironment at levels comparable to the native 
tumor matrix, while eliminating tension-dependent 
changes in cell shape by using blebbistatin, a 
well-known selective inhibitor of non-muscle myosin 
II [47]. Cell morphology in blebbistatin-treated 
samples was different from untreated controls (Fig. 
2E), with a partial disassembly of cell aggregates (Fig. 
2E) and a shift of the exosome size distribution curve 
to higher values (Fig. 2F) when tensional forces within 
the cells were modified in a 3D setting.  
Exosome cargo. Based on these findings, one 
could hypothesize that the exosome size is not the 
only property controlled by the microenvironment, 
and that their cargo is also a subject to regulation. To 
test this hypothesis, we analyzed the exosomal mRNA 




cargo and focused on EZH2, one of the most 
important mediators of Ewing’s sarcoma tumor 
growth and progression.  
First, we confirmed the overexpression of EZH2 
in ES tumors at mRNA levels using the R2 Genomics 
Analysis and Visualization Platform (http://r2.amc. 
nl), by comparing the gene profiles for ES tumors (arrays 
from Francesconi n=37, and Delattre; n=117) and 
healthy tissues (array from Roth n=353) (Fig.3A). We 
also checked EZH2 overexpression in ES tumors by 
Immunohistochemistry (data not shown). 
Interestingly, the EZH2 protein was almost 
undetectable by Western blot in ES cells cultured in 
monolayers (Fig. 3B), which also expressed low levels 
of EZH2 mRNA by qRT-PCR (Fig. 3C). However, 
EZH2 mRNA and EZH2 protein increased in 
TE-tumors, both at the protein level (Fig. 3B) and at 
the mRNA level (Fig. 3C). These data supported the 
notion that a native-like environment can modulate 
cancer biology and mimic, at least in part, the 
properties of real tumors.  
 
 
Figure 3. Effects of engineered microenvironment on exosome cargo. (A) EZH2 mRNA expression in Ewing's Sarcoma tumors and healthy tissues using publicly 
available expression array data; BoxBlot presentation using a comparative study of the amc onco-genomics software tool (www.amc.com). Ewing’s sarcoma samples (ES) used in 
the analysis belong to Francesconi’s array and to Delattre’s array and Healthy set to the Roth’s array. The numbers of samples in each cohort are indicated. (B) Protein levels of 
EZH2 in SK-N-MC cell monolayers (day 3) and bioengineered tumors (day 3 and day 7). (C) qRT-PCR of EZH2 expression indicates 2-fold increase of expression in 
bioengineered tumors over 7 days of cultivation (SF d7) as compared to cell monolayers (ML). Relative endogenous expression of EZH2 was normalized to actin; error bars 
represent standard deviation of relative expression. Statistical significance was determined by the two-tailed Student’s t test. *p < 0.05; ns, not significant. (D) EZH2 mRNA in 
exosomes released from SK-N-MC cell monolayers and bioengineered tumors at days 3 and 7 (by qRT-PCR). The measured amounts of EZH2 mRNA were normalized to 
U6SnRNA; error bars represent standard deviation of relative expression. Statistical significance was determined by the two- tailed Student’s t test. ∗∗p < 0.01 (E) Levels of EZH2 
mRNA in exosomes isolated from blood plasma from Ewing’s sarcoma type 1 patients, healthy donors, non-type 1 Ewing sarcoma patients, and an osteosarcoma patient. 




Then, we isolated exosomes released from the ES 
cells cultured in monolayers and bioengineered 
tumors. We found high levels of EZH2 mRNA in 
exosomes from TE-tumors, both at day 3 and day 7, 
when compared to monolayers (Fig. 3D). 
Importantly, the measured levels of EZH2 in 
bioengineered tumors corresponded to those in the 
blood plasma of ES patients. EZH2 mRNA was 
detected in exosomes from Ewing’s sarcoma type-1 
plasma (n=4), but not in plasma of healthy donors 
(n=4), non-type 1 patients (n=3) or an osteosarcoma 
patient (n=1) (Fig. 3E).  
Transfer of exosome cargo. Because EZH2 
induces an aberrant phenotype of Ewing’s sarcoma in 
vivo and also affects the hMSCs cultured in vitro [28], 
we investigated whether the exosomes containing 
EZH2 mRNA can transfer their cargo to the cells 
hMSCs normally present in the bone niche. To this 
end, we labeled exosomes derived from the TE-tumor 
(Exo-TE-tumor) with the green RNA-selective nucleic 
acid stain SYTO RNASelect at day 7, the time point at 
which we observed high levels of EZH2 mRNA in 
these exosomes. The exosomes from the TE-tumors 
were taken up by bone marrow derived hMSCs, after 
12 hours of incubation compared to the technical 
control (PBS treated with SYTO RNASelect) (Fig. 4A). 
Significant increases in EZH2 mRNA levels were 
detected in hMSC treated with exosomes from 
TE-tumors, when compared with untreated hMSCs or 
hMSCs treated with hMSC-derived exosomes (Fig. 
4B).  
Finally, we analyzed the effects of exosomes 
secreted by bioengineered tumors on human 
osteoblasts (hOB) and human osteoclasts (hOC). 
Labeled exosomes from TE-tumors were taken up by 
both hOB (4C) and hOC (4E). However, this uptake 
had no effect on EZH2 mRNA levels in hOB (4D), and 
resulted in down-regulation of EZH2 in hOC (4F). 
These data confirm that EZH2 mRNA-loaded 
exosomes can be transferred in vitro from cancer cells 
to cell populations from the bone niche, with different 
effects on hMSC (upregulation of EZH2), hOC 
(downregulation of EZH2) and hOB (no effect). 
Discussion 
We studied tumor-secreted exosomes, from two 
complementary views: effects of the tumor 
microenvironment on exosome size and cargo, and 
the ability of exosomes to transfer key regulators from 
their cargo to the surrounding non-cancer cells in the 
tumor niche. To this end, we report the first 
bioengineering study of tumor-secreted exosomes and 
show that these exosomes more closely match in vitro 
the size distribution and mRNA cargo found in the 
exosomes from blood plasma of tumor patients. This 
result was achieved using a tumor model, formed by 
culturing tumor cells in scaffolds designed to mimic 
the native tumor niche (Fig. 1A), and could not be 
achieved in tumor cell monolayers or tumor cell 
aggregates. The studies were done using Ewing’s 
Sarcoma as a clinically relevant example of aggressive 
bone tumor characterized by expression of 
EWSR1-FLI1 fusion protein [48], which induces 
expression of EZH2 [28]. We therefore focused the 




Figure 4. Exosome-mediated 
transfer of EZH2 mRNA. Confocal 
images of (A) human mesenchymal 
stem cells (hMSC), (B) human 
osteoblasts (hoB), and (C) human 
osteoclasts (hOC) after 2h of 
incubation with exosomes released 
from bioengineered tumors after 7 
days of cultivation (+exo TE-tumor) 
labeled with SYTO RNA Select green 
fluorescent. PBS treated with SYTO 
RNA Select was used as technical 
control of the experiment. Data show 
representative images from 3 
independent studies. EZH2 mRNA 
levels in (D) hMSC, (E) hOB and (F) 
hOC treated for 12 hours with 
exosomes released from 
bioengineered tumors after 7 days of 
cultivation (+exo TE-tumor). 
Statistical significance was determined 
by the two-tailed Student’s t test. 








In recent years, major progress has been made 
with developing advanced 3D models that capture in 
vitro selected factors of the in vivo tumor 
microenvironment, with the aid of tissue engineering 
methods [14]. In line with the view that a 
bioengineered tumor should be a simplified version of 
reality tailored towards addressing a specific 
biological question, we aimed to engineer a 
“minimally functional unit” with capability to 
recapitulate the size and cargo of tumor exosomes. 
First, we evaluated the individual and collective 
effects of the bioengineered tumor niche on the size of 
exosomes. In a multicellular organism, tissue cells are 
highly organized in a 3-dimensional fashion, and are 
surrounded by the extracellular matrix [13]. Tumors 
are also organ-like structures made up of many 
individual cells, where the 3-dimensionality and the 
extracellular matrix composition and stiffness play 
critical roles in tumor development [13, 49-51]. It is 
not surprising that multiple microenvironmental 
signals (including the 3-dimensionality of the 
extracellular matrix, matrix composition and stiffness, 
and the acting tensile forces) are important for 
recapitulating the size of exosomes found in native 
tumors. Neither 3-dimensionality alone (tumor 
aggregates) nor the composition alone (cell 
monolayers on polystyrene dishes coated with 
extracellular matrix components) recapitulated the 
size values found in plasma of ES patients. 
Interestingly, we also observed different expression 
levels in the conventional exosomal marker CD81 
between cells in monolayer and in TE-tumor models. 
Interestingly, CD81 levels were decreased and were 
almost undetectable in the TE-tumor-derived 
exosomes. This phenomenon is also observed in 
Peinado et. al. [8] but with the exosomal HSC70 
marker that fluctuates in levels between patients and 
stages. This suggests that patients conditions and in 
our case, culture conditions (3-dimensionality, 
hypoxia, microenvironment composition, stiffness…) 
may regulate the conventional or established markers 
for exosomes characterization.  
In summary, these findings reinforce the idea 
that a simplified but realistic version of the tumor 
complexity, designed to address a specific question of 
interest, could in fact provide a platform for cancer 
research.  
We found that EZH2 mRNA was present in 
exosomes secreted from TE-tumors at much higher 
levels than in exosomes secreted from tumor cells 
cultured in monolayers. Thus, our data suggest that 
ES tumors in vivo may also produce exosomes 
enriched in EZH2 mRNA. Importantly, we confirmed 
that EZH2 mRNA was only detectable in exosomes 
from plasma in Ewing’s sarcoma type 1, and not in 
plasma of healthy donors or patients with other types 
of sarcoma tumors. Again, these findings support the 
utility of the TE tumor model for cancer research and 
suggest that exosomes should be studied in 
native-like experimental settings, rather than in cell 
monolayers or cell aggregates.  
Our data are consistent with the known roles of 
exosomes as mediators of cancer progression. 
Transfer of paracrine signals to the healthy 
surrounding cells was shown to modulate the 
behavior of these cells and to create paths of low 
resistance for tumor invasion. Uptake of exosomes 
secreted by the TE tumor by the cells present in the 
bone niche resulted in different effects for different 
cell types with respect to the expression of EZH2 
mRNA: up-regulation in hMSC, down-regulation in 
osteoclasts and no effect in osteoblasts.  
MSC can be recruited in large numbers to the 
tumor stroma, to enhance tumor growth 
and metastasis [52]. A very interesting recent result is 
that the melanoma-derived exosomes favor the 
metastasis of primary tumors by modulating bone 
marrow progenitors [8]. On the other hand, MSC can 
be transformed by expression of EWSR1-FLI1 fusion 
protein [53], to create a permissive cellular 
environment for mutations and oncogene 
up-regulation, with significant molecular 
plasticity.[17, 53, 54]. A number of reports suggested 
that hMSCs are the cells of origin that give rise to 
Ewing’s sarcoma [20]. In our system, hMSCs 
displayed increased levels of EZH2 mRNA after 
treatment with exosomes secreted from TE-tumors. 
Based on these results, we postulate that tumor cells 
may induce epigenetic changes in hMSCs from the 
stromal compartment, by releasing EZH2 mRNA 
from their exosomes. Epigenetic changes such as gene 
promoter methylation in stromal cells have been 
associated with malignancy. However, histone 
modifications (i.e., H3K27me3 established by EZH2) 
and chromatin remodeling in the cells comprising 
tumor microenvironment remain largely unknown 
and will require further studies.  
Interestingly, tumor-secreted exosomes 
down-regulated EZH2 mRNA in the bone osteoclasts, 
an effect not previously documented. However, a 
correlation was recently established between EZH2 
levels and the expression of the microRNA-34a[55], a 
microRNA involved in suppressing osteoclasto-
genesis, bone resorption and bone metastasis [56]. The 
mechanism for the observed downregulation of EZH2 
mRNA in healthy osteoclasts could thus involve 
miR34a, with direct effects on bone resorption and 
tumor progression. However, systematic studies will 
be needed to determine if there is a link between 
EZH2 and osteoclast homeostasis.  




This study also has limitations. For example, we 
report that there were no changes in EZH2 levels in 
hOB after these cells were treated with exosomes 
secreted from TE-tumors. However, the studies of 
EZH2 mRNA transfer were performed in monolayer 
cultures, which do not provide a proper context of the 
bone niche. At this point, one cannot exclude 
additional or alternate effects of EZH2 mRNA on the 
cells from the bone niche within the Ewing’s sarcoma 
tumor context. Further studies using models of the ES 
tumor and the surrounding bone may be necessary to 
unravel the direct role of EZH2 in bone homeostasis.  
In summary, we developed a bioengineered 
tumor model for broad use in cancer research, using 
Ewing sarcoma as a clinically relevant example. 
Unlike cell monolayers and aggregates, this model 
recapitulates the size and cargo of exosomes found in 
patients’ blood plasma. We show that the 
microenvironmental signals (including the 
3-dimensionality, composition, and stiffness of the 
tumor matrix) are necessary for recapitulating the 
properties of exosomes found in native tumors. Using 
this model, we investigated the effects of the tumor 
microenvironment on exosome size and cargo, the 
role of physical signals, and the ability of exosomes to 
transfer key regulators to the surrounding non-cancer 
cells of the bone niche (bone marrow mesenchymal 
stem cells, osteoblasts, osteoclasts). We suggest that 
the proposed bioengineered model could serve as an 
effective tool in studies of human tumor exosomes. 
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